Oragenics, Inc.
June 16, 2025
Company Presentation
Brain Health
Oragenics is a clinical stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, entering Phase II clinical studies for the treatment of mild traumatic brain injury (mTBI) or concussion. The Company is also advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration.
Company HQ City:
Sarasota
Company HQ State:
FL
Company HQ Country:
United States
Year Founded:
1996
Lead Product in Development:
ONP-002 a NCE neurosteroid, delivered by a novel intranasal device for the treatment of mTBI (concussion)
CEO
Janet Huffman - Interim CEO and CFO
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
ONP-002 for the treatment of mTBI (concussion)
ONP-001 for the treatment of various rare leukodystrophies
Exchange
NYSE
Ticker
OGEN
When you expect your next catalyst update?
Start of ONP-002's Phase 2a clinical study by end of Q2 2025
What is your next catalyst (value inflection) update?
June 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}